Current Problems in Cardiology
Volume 32, Issue 5 , Pages 268-314 , May 2007

HDL Cholesterol: Physiology, Pathophysiology, and Management

  • Jeffrey J. Link, MD

      Affiliations

    • Dr. Link and Dr. Rohatgi have no conflict of interest to disclose.
    • ,
  • Anand Rohatgi, MD

      Affiliations

    • Dr. Link and Dr. Rohatgi have no conflict of interest to disclose.
    • ,
  • James A. de Lemos, MD

      Affiliations

    • Dr. de Lemos has received lecture honoraria from Merck/Schering and Pfizer and consulting fees from Pfizer.
    • Corresponding Author InformationAddress reprint requests to: James A. de Lemos, MD, UT Southwestern Medical Center, 5909 Harry Hines Blvd., HA 9.133, Dallas, TX 75390-9047.

References 

  1. Gordon T, Castelli WP, Hjortland MC, et al. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med. 1977;62:707–714
  2. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein and cardiovascular disease (Four prospective American studies). Circulation. 1989;79:8–15
  3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;354:937–952
  4. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination surveys. JAMA. 1993;269:3002–3008
  5. Rubins HB, Robins SJ, Collins D, et al. Department of Veterans Affairs HDL Intervention Trial Study Group Distribution of lipids in 8500 men with coronary artery disease. Am J Cardiol. 1995;75:1196–1201
  6. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002;105(12):1424–1428
  7. Goulinet S, Chapman MJ. Plasma LDL and HDL subspecies are heterogeneous in particle content of tocopherols and oxygenated and hydrocarbon caretenoids (Relevance to oxidative resistance and atherogenesis). Arterioscler Thromb Vasc Biol. 1997;17:786–796
  8. Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis; the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45:993–1007
  9. Gordon DJ, Rifkind BM. High-density lipoprotein—the clinical implications of recent studies. N Engl J Med. 1989;321:1311–1316
  10. Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Vasc Biol. 2003;23:712–719
  11. Wang N, Silver DL, Thiele C, et al. ATP-binding cassette transporters G1 and G4 mediate cellular efflux to high densiy lipoproteins. Proc Natl Acad Sci USA. 2004;101:9774–9779
  12. Barter PJ, Kastelein JJ. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol. 2006;47:492–499
  13. Williams DL, Connelly MA, Temel RE, et al. Scavenger receptor B1 and cholesterol trafficking. Curr Opin Lipid. 1999;10:329–339
  14. Schwartz CC, VandenBroek JM, Cooper PS, et al. Lipoprotein cholesteryl ester production, transfer and output in humans. J Lipid Res. 2004;45:1594–1607
  15. Puchois P, Kaul S, Nilsson J, et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis. 1987;68:35–40
  16. Huang Y, von Eckardstein S, Wu S, et al. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol. 1995;15:1412–1418
  17. Fan YM, Salonen JT, Koivu TA, et al. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction (A prospective population study in eastern Finnish men). Circulation. 1991;84:129–139
  18. Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial. Arterioscler Thromb Vasc Biol. 2005;25:2185–2191
  19. Yla-Herttuala S. Oxidized LDL and atherogenesis. Ann NY Acad Sci. 1999;874:134–137
  20. Parthasarathy S, Barnett J, Fong LG, et al. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein (PG-275-83). Biochim Biophys Acta. 1990;1044:275–283
  21. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481–488
  22. Galle J, Ochslen M, Schollmeyer P, et al. Oxidized lipoproteins inhibit endothelium-dependent vasodilation (Effects of pressure and high-density lipoprotein). Hypertension. 1994;23:556–564
  23. Libby P, Ridker PM, Maseri A, et al. Inflammation and atherosclerosis. Circulation. 2002;1135–1143
  24. Dimayuga P, Zhu J, Oguchi S, et al. Reconstituted HDL containing apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun. 1999;264:465–468
  25. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1 induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 2001;103:108–112
  26. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399–1402
  27. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high-density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276;34480-5.
  28. Ansell BJ, Watson KE, Fogelman AM, et al. High-density lipoprotein function: recent advances. JACC. 2005;46:1792–1798
  29. Yuhanna IS, Zhu Y, Cox BE, et al. High density lipoprotein binding to scavenger receptor-B1 activates endothelial nitric oxide synthase. Nat Med. 2001;7:853–857
  30. Li XA, Titlow WB, Jackson BA, et al. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide syntase in a ceramide-dependent manner. J Biol Chem. 2002;277:11058–11063
  31. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apotosis by high-density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Clin Invest. 2004;113:569–581
  32. Fleisher LN, Tall AR, Witte LD, et al. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem. 1982;257:6653–6655
  33. Horio T, Kohno M, Yasunari K, et al. Stimulation of endothelin-1 release by low density and very low density lipoproteins in cultured human endothelial cells. Atherosclerosis. 1993;101:185–190
  34. Kuhn FE, Mohler ER, Satler LF, et al. Effects of high-density lipoprotein on acetylcholine-induced vasoreactivity. Am J Cardiol. 1991;68(15):1425–1430
  35. Saku K, Ahmed M, Glass-Greewal P, et al. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res. 1985;39(1):1–8
  36. Nofer JR, Walter M, Kehrel B, et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol. 1998;18:861–869
  37. Curtiss LK, Plow EF. Interaction of plasma lipoproteins with human platelets. Blood. 1984;64:365–374
  38. Griffin JH, Kojima K, Banka CL, et al. High density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 1999;103:219–227
  39. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults. (Adult Treatment Panel III). Final Report. Circulation. 2002;106:3143–3421
  40. Assmann G, von Eckardstein A, Funke H, et al. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 87;III28-34.
  41. Patel SB, Honda A, Salen G, et al. Mapping a gene involved in regulating dietary cholesterol absorption. (The sitosterolemia locus is found at chromosome 2p21). J Clin Invest. 1998;102(5):1041–1044
  42. Hobbs HH, Russell DW, Brown MS, et al. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet. 1990;24:133–170
  43. Knoblauch H, Bauerfeind A, Toilat MR, et al. Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet. 2004;13:993–1104
  44. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004;89:4963–4971
  45. Lamon-Fava S, Wilson PWF, Schaefer EJ, et al. Impact of BMI on coronary heart disease risk factors in men and women; the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1996;16:1509–1515
  46. Datillo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–328
  47. Ginsberg HN, Kris-Etherton P, Dennis B, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA study, protocol 1. Arterioscler Thromb Vasc Biol. 1998;18:441–449
  48. Ginsberg H. Nonpharmacologic management of low levels of high-density lipoprotein cholesterol. Am J Cardiol. 2000;86(s):41L–45L
  49. Lichtenstein AH, Ausman LM, Jalbert SM, et al. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med. 1999;340:1933–1940
  50. Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med. 2001;161(18):2185–2192
  51. Nestel PJ, Connor WE, Reardon MF, et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest. 1984;74(1):82–89
  52. Harris WS. N-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 1996;31:243–252
  53. Frenais R, Ouguerram K, Maugeais C, et al. Effect of dietary -3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus. Atherosclerosis. 2001;157:131–135
  54. Thompson PD. What do muscles have to do with lipoproteins?. Circulation. 1990;81:1428–1430
  55. Zmuda JM, Yurgalevitch SM, Flynn MM, et al. Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol. Atherosclerosis. 1998;137:215–221
  56. Hardman AE, et al. Role of exercise and weight loss in maximizing LDL cholesterol reduction. Eur Heart J Suppl. 1999;1(suppl S):S123–S131
  57. An P, Borecki IB. Evidence of major genes for plasma HDL, LDL cholesterol and triglyceride levels at baseline and in response to 20 weeks of endurance training: the HERITAGE Family Study. Int J Sports Med. 2005;26:414–419
  58. Lakier JB. Smoking and cardiovascular disease. Am J Med. 1992;93:8S–12S
  59. Garrison RJ, Kannel WB, Feinleib M, et al. Cigarette smoking and HDL cholesterol: the Framingham Offspring Study. Atherosclerosis. 1978;30:17–25
  60. Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: a meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319:1523–1528
  61. Lin RC, Lumeng L. Effect of chronic ethanol feeding on high density lipoprotein subfractions in rats. Alcohol Clin Exp Res. 1991;15:207–211
  62. Kashyap ML, Tavintharan S, Kamanna VS. Optimal therapy of low levels of high density lipoprotein-cholesterol. Am J Cardiovasc Drugs. 2003;3(1):53–65
  63. Jin FY, Kamanna VS, Kashyap ML, et al. Niacin accelerates intracellular ApoB degredation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol. 1999;19:1051–1059
  64. Jin FY, Kamanna VS, Kashyap ML, et al. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells (Implication for reverse cholesterol transport). Arterioscler Thromb Basc Biol. 1997;17:2020–2028
  65. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517
  66. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  67. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298
  68. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142:95–104
  69. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. JACC. 1986;8(6):1245–1255
  70. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol. 2003;91(12):1432–1436
  71. Probstfield JL, Hunninghake DB. Nicotinic acid as a lipoprotein-altering agent (Therapy directed by the primary physician). Arch Intern Med. 1994;154:1557
  72. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia (A prospective trial). Arch Intern Med. 1994;154:1586–1595
  73. Staels B, Dallongeville J, Schoonjans K, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093
  74. Chawla A, Boisvert WA. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53–58
  75. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418
  76. Guyton JR, Blazing MA, Hagar J, et al. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia. Arch Intern Med. 2000;160:1177–1184
  77. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861
  78. McKenney JM, McCormick LS, Weiss S, et al. Role of fibrates in the management of hypertriglyceridemia. Am J Cardiol. 1999;83(9B):30F–35F
  79. Schaefer JR, Schweer H, Ikewaki K, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis. 1999;144:177–184
  80. Chapman MJ. Are the effects of statins on HDL-cholesterol clinically relevant?. Eur Heart J. 2004;6(suppl C):C58–C63
  81. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577–581
  82. Jones P, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvistatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152–160
  83. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000;102:1893–1900
  84. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  85. Cannon CP, Braunwald E, McCabe CH, et al. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  86. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–484
  87. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA. 1998;279:1615–1622
  88. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274–1275
  89. http://www.clinicaltrials.gov/ct/show/NCT00120289?order=1
  90. http://www.clinicaltrials.gov/ct/show/NCT00000620?order=4
  91. Zetia (ezetimibe) package insert. Kenilworth, NJ: Schering Corporation, 2002.
  92. Altmann SW, Davis HR, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201–1204
  93. Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs. 2002;62:2333–2347
  94. Ballantyne CM, Houri J, Notabartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409–2415
  95. Lehmann JM, Lenhard JM, Oliver BB, et al. An antidiabetic thiazoladinedione is a high affinity ligand for peroxisome proliferators-activated receptor-gamma (PPAR-gamma). J Biol Chem. 1995;270:12953–12956
  96. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferators-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun. 2000;278:704–711
  97. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPAR-γ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2005;115:1323–1332
  98. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351;11:1106-18.
  99. Szapary PO, Bloedon LAT, Samaha FF, et al. Effects of pioglitazone on lipoproteins, inflammatory markers and adipokines in nondiabetic patients with metabolic syndrome. Atherioscler Thromb Vasc Biol. 2006;26:182–188
  100. Dormandy JA, Charbonnel B, Eckland DLA, et al. Secondary prevention of macrovascular events in patients with type two diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial I macrovascular Events): a randomized control trial. Lancet. 2005;366:1279–1289
  101. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia. Diabetes Care. 2005;28:1547–1554
  102. Cabrero A, Cubero M, Llaver G, et al. Differential effects of peroxisome proliferator-activated receptor activators of the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003;52:652–657
  103. Winkler K, Konrad T, Fullert S, et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care. 2003;26:2588–2594
  104. Gerstein HC. Rationale, design and recruitment of a large, simple, international trial of diabetes prevention: the DREAM trial. Diabetologica. 2004;47:1519–1527
  105. Saad MF, Greco S, Osei K, et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects. Diabetes Care. 2004;27(6):1324–1329
  106. Nissen SE, Wolski K, Topol EJ, et al. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581–2586
  107. Miller KW, Lane MD. Estradiol-induced alteration of very-low-density lipoprotein assembly (Possible competition among apoproteins for incorporation into nascent very-low-density lipoprotein). J Boil Chem. 1984;259:15277–15286
  108. Walsh BW, Schiff I. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196–1204
  109. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the ris of coronary heart disease. N Engl J Med. 2003;349:523–534
  110. Grey AB, Stapleton JP, Evans MC, et al. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995;3191–3195
  111. Barrett-Connor E, Mosca L, Collins P, et al. Effects of Raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–137
  112. Van Lenten BJ, Wagner AC, Nayak DP, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response (Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures). J Clin Invest. 1995;96:2758–2767
  113. Despres J-P, Golay A, Sjostrom L, et al. Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–2134
  114. Van Gaal LF, Rissanen Am, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397
  115. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761–775
  116. Franceschini G, Magani D. Relationship of the phenotypic expression of apo-A-I Milano apoprotein with plasma lipid and lipoprotein patterns. Circulation. 1998;97:780–785
  117. Gualandri V, Franceschini G, Sirtori CR, et al. Identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet. 1985;37:1083–1097
  118. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda Study. Circulation. 2001;103:1949–1954
  119. Franceschini G, Calabresi L, Chiesa G, et al. Increased cholesterol efflux potential of sera from apo-A-I Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol. 1999;19:1257–1262
  120. Shah PK, Yano J, Reyes O, et al. High dose recombinant apo-A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein-e deficient mice. Circulation. 2001;103:3047–3050
  121. Nissen S, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA. 2003;290:2292–2300
  122. Navab M, Anantharamaiah GM, Reddy ST, et al. Human apolipoprotein A-I and A-I mimetic peptides:potential for atherosclerosis reversal. Curr Opin Lipidol. 2004;15:645–649
  123. Brown ML, Inazu A, Hesler CB, et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 1989;342:448–451
  124. Ordovas JM. Association of cholesteryl ester transfer protein-TaqB1 polymorphism with variations in lipoprotein subclasses and coronary heart disease ris:the Framingham study. Arteriosclerosis Vasc Biol. 2000;20:1323–1329
  125. Okamato H, Yonemori F. A cholesteryl ester transfer protein attenuates atherosclerosis in rabbits. Nature. 2000;406:203–207
  126. Morehouse LA. The CETP-inhibitor Torctrapib raises HDL and prevents aortic atherosclerosis in rabbits. Presented at XV International Symposium on Drugs Affecting Lipid Metabolism, October 24 to 27, 2004, Venice, Italy.
  127. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model or atherosclerosis. Ateriosclerosis Thromb Vasc Biol. 2000;20:2106–2112
  128. Huang Z, Inazu A, Nohara A, et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond). 2002;103:587–594
  129. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97:2917–2923
  130. Klerkx AH, de Grooth GJ, Zwinderman AH, et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest. 2004;34:21–28
  131. Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women:the prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk population study. Circulation. 2004;110:1418–1423
  132. De Grooth GJ, Smilde TJ, Van Wissen S, et al. The relationship between cholesteryl ester transfer protein levels and risk profile in patients with familial hypercholesterolemia. Atherosclerosis. 2004;173:261–267
  133. Davidson MH, Maki K, Umporowicz D, et al. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 2003;169:113–120
  134. De Grooth GJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105:2159-65.
  135. Kuivenhoven JA, Stalenhoef AF. Inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol. 2005;95:1085–1088
  136. Bisoendial RJ, Hovingh GK, Harchaoui K, et al. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol. 2005;25:e133–e134
  137. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24:490–497
  138. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505–1515
  139. Clark RW, Ruggieri RB, Cunningham D, et al. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47:537–552
  140. Davison M. Efficacy and safety of a novel CETP inhibitor torcetrapib administered with and without atorvastatin in subjects with a low level of HDL-C. Am Coll Cardiol Scientific Session 2005 March 6-9 2005, Orlando, FL.
  141. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005;25:1057–1064
  142. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults. (Adult Treatment Panel III). Final Report. Circulation. 2002;106:3142–3421
  143. American Diabetes Association Position Statement. (Dyslipidemia management in adults with diabetes). Diabetes Care. 2004;27(suppl 1):S68–S71
  144. Mosca L, Appel LJ, Benjamin EJ, et al. American Heart Association Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109(5):672–693
  145. Harper CR, Jacobson TA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 1999;159(10):1049–1057

PII: S0146-2806(07)00005-9

doi: 10.1016/j.cpcardiol.2007.01.004

Current Problems in Cardiology
Volume 32, Issue 5 , Pages 268-314 , May 2007

Article Tools

* Image Usage & Resolution